Tislelizumab plus SYS6010 for advanced lung cancer after immunotherapy
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a combination of two drugs, tislelizumab (an immunotherapy) and SYS6010, for people with advanced non-small cell lung cancer whose cancer has gotten worse after prior immunotherapy. It aims to see if this new combination can help when standard treatments have stopped working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced non-small cell lung cancer that cannot be removed with surgery or cured with radiation.
- Your cancer does not have certain gene changes (EGFR, ALK, or ROS1).
- You have already received an immunotherapy drug (like Keytruda or Opdivo) and your cancer got worse while on it or after it.
- You have at least one tumor that can be measured on scans.
- You are able to walk and take care of yourself (ECOG score 0 or 1).
- You agree to have a tumor biopsy before and during treatment if it can be done safely.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests combining the immunotherapy drug tislelizumab with radiation therapy for people with advanced non-squamous non-small cell lung cancer that hasn't been treated before. It aims to see if this combination helps control the cancer better than standard treatments.
This trial tests a combination of platinum-based chemotherapy, large fractionated radiotherapy, and the immunotherapy drug tislelizumab for people with stage IIIB to IV non-squamous non-small cell lung cancer. It aims to see if this approach can help control the cancer without certain gene mutations.
This trial tests a new treatment for people with non-small cell lung cancer (NSCLC) that was removed by surgery but did not completely disappear after pre-surgery chemoimmunotherapy. The treatment combines your own tumor-fighting cells (L-TIL, grown from your tumor) with an immunotherapy drug (tislelizumab) to try to keep the cancer from coming back.
This study tests a combination of three treatments—an immunotherapy drug called tislelizumab, chemotherapy, and a procedure called BACE—for advanced lung cancer that cannot be surgically removed. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial tests whether a new drug combination (SYS6010 plus enlonstobart) works better than standard immunotherapy with chemotherapy for patients with advanced non-small cell lung cancer. You may qualify if you have not received prior cancer treatment and have a specific marker (PD-L1) on your tumor.
This trial tests a combination of two drugs (tislelizumab and anlotinib) for people with advanced lung cancer whose first immunotherapy treatment stopped working. The goal is to see if this new combination can help when the first treatment stopped being effective.
Hear when a new NSCLC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.